Samsung Biologics Q3 Net Income Declines Over 20%

Samsung Biologics Co., the biotechnology division of Samsung Group, has reported a net profit of 391.1 billion won (approximately $295.2 million) for the third quarter of 2026, marking a decline of 21.2% compared to the same period last year.

Despite the drop in net income, the company saw an increase in operating profit, which rose to 640.1 billion won from 633.5 billion won a year earlier. Revenue also increased by 18.5%, reaching 1.49 trillion won, attributed to the full-scale operations of its four plants located in Songdo and the ramp-up of production at its fifth facility.

The decline in net income reflects ongoing challenges within the biotechnology sector, compounded by global economic pressures. Samsung Biologics has been expanding its contract development and manufacturing organization (CDMO) services, with cumulative contract orders for the year reaching $22 billion.

In light of these developments, the company has raised its annual sales guidance for 2026, now forecasting a growth of 20%, up from the previous estimate of 15-20%. This adjustment is based on the stable growth observed in its production facilities.